Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10
Sponsor: Sinocelltech Ltd.
Summary
Phase Ia to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of SCTB10 following a single dose in healthy participants
Official title: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Single and Multiple Doses of SCTB10 in Healthy Participants and Patients With Hemophilia A
Key Details
Gender
MALE
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-09-30
Completion Date
2029-08-30
Last Updated
2026-09-29
Healthy Volunteers
Yes
Conditions
Interventions
SCTB10
SCTB10 will be subcutaneously administered as a single dose in healthy volunteers
Placebo
Placebo will be subcutaneously administered in Healthy Volunteers
Locations (1)
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China